JPMorgan Chase & Co. Buys Shares of 79,470 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

JPMorgan Chase & Co. purchased a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 79,470 shares of the biopharmaceutical company’s stock, valued at approximately $155,000. JPMorgan Chase & Co. owned about 0.10% of Catalyst Pharmaceuticals as of its most recent SEC filing.

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Several other large investors also recently made changes to their positions in the stock. Candriam Luxembourg S.C.A. bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at about $1,170,000. Oxford Asset Management raised its stake in shares of Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 34,181 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares during the period. 30.28% of the stock is currently owned by institutional investors.

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) opened at 2.77 on Friday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $0.94 and a 12-month high of $3.20. The company’s market capitalization is $234.21 million. The firm’s 50-day moving average is $2.88 and its 200-day moving average is $2.05.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, equities analysts predict that Catalyst Pharmaceuticals, Inc. will post ($0.23) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “[[title]]” was reported by [[site]] and is owned by of [[site]]. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at [[permalink]].

CPRX has been the topic of several research reports. Zacks Investment Research raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a report on Monday, May 22nd. Piper Jaffray Companies set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.